References

avk

Архивъ внутренней медицины

The Russian Archives of Internal Medicine

2226-67042411-6564

“SINAPS” LLC

10.20514/2226-6704-2020-10-6-414-421

avk-1104

Research Article

ОБЗОРНЫЕ СТАТЬИ

REVIEW ARTICLES

Фактор некроза опухоли-альфа и возрастассоциированная патология

Tumor Necrosis Factor-Alpha and Age-Related Pathologies

https://orcid.org/0000-0002-4131-8432

Тополянская

С. В.

Topolyanskaya

S. V.

Светлана Викторовна Тополянская

Кафедра госпитальной терапии № 2

Москва

Svetlana V. Topolyanskaya

Hospital Therapy Department № 2

Moscow

sshekshina@yahoo.com

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения РФ (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), RF Health MinistryRussian Federation

2020

02122020

106414421

2020

Тополянская С.В.

Topolyanskaya S.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.medarhive.ru/jour/article/view/1104

В обзоре отражены современные представления о понятии «inflammaging» и роли субклини ческого воспаления при различной возрастассоциированной патологии. Особое внимание уделено фактору некроза опухоли-α — ключевому цитокину, принимающему важное участие как в патогенезе хронических воспалительных заболеваний, так и в процессах старения. Повышенное содержание фактора некроза опухоли-α приводит к возникновению и прогрессированию различных заболеваний, к усугублению старческой астении, к инвалидизации и смертности лиц пожилого и старческого возраста. Фактор некроза опухоли-α оказывает влияние на различные факторы риска сердечно-сосудистой патологии, способствует возникновению и прогрессированию атеросклероза и связанных с ним заболеваний. Этот цитокин может усугублять также различные метаболические нарушения, в первую очередь, инсулинорезистентность и сахарный диабет. Фактор некроза опухоли-α — ключевой цитокин, стимулирующий костную резорбцию (с возникновением остеопороза) и саркопению. Имеющиеся в нас тоящее время данные подтверждают важную роль фактора некроза опухоли-α при различных возраст-ассоциированных заболеваниях.

Modern concepts about the «inflammaging» and the role of subclinical inflammation in various age-associated pathology are described in the review. Particular attention is paid to the tumor necrosis factor-α, a key cytokine that plays an important role in the pathogenesis of chronic inflammatory diseases as well as in aging. The increased levels of tumor necrosis factor-α leads to the onset and progression of various diseases, to severity of frailty, to disability and mortality of elderly persons. Tumor necrosis factor-α affects different risk factors for cardiovascular diseases, contributes to the onset and progression of atherosclerosis and related pathology. This cytokine can also aggravate various metabolic disorders, mainly — insulin resistance and diabetes mellitus. Tumor necrosis factor-α is a key cytokine that stimulates bone resorption (up to osteoporosis) and sarcopenia (up to cachexia). Currently available data confirm the important role of tumor necrosis factor-α in various age-associated disorders.

воспалениецитокиныфактор некроза опухоли-α (ФНО-α)атеросклерозстарениестарческий возрастдолгожители

inflammationcytokinestumor necrosis factor-α (TNF-α)atherosclerosisagingold agelong-livers

References1

Franceschi C., Bonafe M., Valentin S., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-54. DOI: 10.1111/j.1749-6632.2000.tb06651.x.

Xia S., Zhang X., Zheng S., et al. An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment. J. Immunol. Res. 2016; 2016(8):1–8. DOI:10.1155/2016/8426874.

Minciullo P.L., Catalano A., Mandraffino G., et al. Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity. Arch. Immunol. Ther. Exp. (Warsz). 2016;64(2):111– 26. DOI: 10.1007/s00005-015-0377-3.

Franceschi C., Capri M., Monti D., et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 2007;128(1):92–105. DOI: 10.1016/j.mad.2006.11.016.

Franceschi C., Olivieri F., Marchegiani F., et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: The lesson of centenarians. Mechanisms of Ageing and Development. 2005;126 (2):351-61. DOI: 10.1016/j.mad.2004.08.028.

Bruunsgaard H., Andersen-Ranberg K., Hjelmborg J.V.B., et al. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med. 2003;115(4):278-83. DOI:10.1016/S0002-9343(03)00329-2.

Bruunsgaard H., Ladelund S., Pedersen A.N., et al. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol. 2003;132:24-31. DOI:10.1046/j.1365-2249.2003.02137.x.

Kany S., Vollrath J.T., Relja B. Cytokines in inflammatory disease. International Journal of Molecular Sciences. 2019;20(23):6008. DOI: 10.3390/ijms20236008.

Urschel K., Cicha I. TNF-α in the cardiovascular system: From physiology to therapy. International Journal of Interferon, Cytokine and Mediator Research. 2015;7:9–25. DOI: 10.2147/IJICMR.S64894.

Wallach D. The cybernetics of TNF: Old views and newer ones. Seminars in Cell and Developmental Biology. 2016;50:105–14. DOI: 10.1016/j.semcdb.2015.10.014.

Bradley J. TNF-mediated inflammatory disease. J. Pathol. 2008;214(2):149-60. DOI: 10.1002/path.2287.

Rea I.M., Gibson D.S., McGilligan V., et al. Age and age-related diseases: Role of inflammation triggers and cytokines. Front Immunol. 2018;9(9):586. DOI:10.3389/fimmu.2018.00586.

Brüünsgaard H., Pedersen B.K. Age-related inflammatory cytokines and disease. Immunol. Allergy Clin. North Am. 2003;23(1):15–39. DOI: 10.1016/S0889-8561(02)00056-5.

Roubenoff R., Parise H., Payette H., et al. Cytokines, insulinlike growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: The Framingham Heart Study. Am. J. Med. Elsevier Inc. 2003;115(6):429–35. DOI: 10.1016/j.amjmed.2003.05.001.

Bruunsgaard H., Benfield T.L., Andersen-Ranberg K., et al. The tumor necrosis factor alpha — 308G > a polymorphism is associated with dementia in the oldest old. J. Am. Geriatr. Soc. 2004;52 (8):1361–6. DOI: 10.1111/j.1532-5415.2004.52369.x.

Cederholm T., Persson M., Andersson P., et al. Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. J. Intern. Med. 2007;262 (2):215-23. DOI: 10.1111/j.1365-2796.2007.01803.x.

Zhang P., Wu X., Li G., et al. Tumor necrosis factor-alpha gene polymorphisms and susceptibility to ischemic heart disease. Medicine (United States). 2017;96(14):e6569. DOI: 10.1097/MD.0000000000006569.

Bruunsgaard H., Skinhoj P., Pedersen A.N., et al. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin. Exp. Immunol. 2000;121(2):255–60. DOI: 10.1046/j.1365-2249.2000.01281.x.

Ait-Oufella H., Taleb S., Mallat Z., et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011;31(5):969-79. DOI: 10.1161/ATVBAHA.110.207415.

Kim H.L., Lee J.P., An J.N., et al. Soluble tumor necrosis factor receptors and arterial stiffness in patients with coronary atherosclerosis. Am. J. Hypertens. 2017;30(3):313–8. DOI: 10.1093/ajh/hpw134.

Kaptoge S., Seshasai S.R.K., Gao P., et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-89. DOI: 10.1093/eurheartj/eht367.

Heinisch R.H., Zanetti C.R., Comin F., et al. Serial changes in plasma levels of cytokines in patients with coronary artery disease. Vasc. Health Risk Manag. 2005;1(3):245–50.

Moreira D.M., da Silva R.L., Vieira J.L., et al. Role of Vascular Inflammation in Coronary Artery Disease: Potential of Antiinflammatory Drugs in the Prevention of Atherothrombosis: Inflammation and Anti-Inflammatory Drugs in Coronary Artery Disease. Am. J. Cardiovasc. Drugs. 2015;15(1):1-11. DOI: 10.1007/s40256-014-0094-z.

Chia S., Qadan M., Newton R., et al. Intra–arterial tumor necrosis factor–α impairs endothelium–dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol. 2003; 23(4): 695–701. DOI: doi.org/10.1161/01.ATV.0000065195.22904.FA

Nakamura M., Yoshida H., Arakawa N., et al. Effects of tumor necrosis factor-α on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J. Cardiovasc. Pharmacol. 2000;36(4):487-92. DOI: 10.1097/00005344-200010000-00011.

Fang W., Wei J., Han D., et al. MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition. Thromb. Res. 2014;133(4):610-5. DOI: 10.1016/j.thromres.2014.01.029.

Sun M., Dawood F., Wen W.H., et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110(20):3221-8. DOI: 10.1161/01.CIR.0000147233.10318.23.

Ridker P.M., Rifai N., Pfeffer M., et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149–53. DOI: 10.1161/01.cir.101.18.2149.

Schumacher S.M., Naga Prasad S.V. Tumor Necrosis Factor-α in Heart Failure: An updated review. Curr Cardiol Rep. 2018;20 (11):117. DOI: 10.1007/s11886-018-1067-7.

Zhu J.X., Liu M.Y., Kennedy R.H., et al. TNF-α-induced impairment of mitochondrial integrity and apoptosis mediated by caspase-8 in adult ventricular myocytes. Cytokine. 2006;34(1-2):96-105. DOI: 10.1016/j.cyto.2006.04.010.

Awad A.E., Kandalam V., Chakrabarti S., et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kγ-dependent manner. Am. J. Physiol. — Cell Physiol. 2010;298(3):679-92. DOI: 10.1152/ajpcell.00351.2009.

Flesch M., Hoper A., Dell’Italia L., et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108(5):598-604. DOI: 10.1161/01.CIR.0000081768.13378.BF.

Tromp J., Khan M.A., Klip U.T., et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J. Am. Heart Assoc. 2017;6(4):e003989. DOI: 10.1161/JAHA.116.003989.

Senni M., D’Elia E., Emdin M., et al. Biomarkers of heart failure with preserved and reduced ejection fraction. Handb. Exp. Pharmacol. 2017;243:79–108. DOI: 10.1007/164_2016_86.

Putko B.N., Wang Z., Lo J., et al. Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology. PLoS One. 2014;9(6):e99495. DOI: 10.1371/journal.pone.0099495.

Bozkurt B., Mann D.L., Deswal A. Biomarkers of inflammation in heart failure. Heart Failure Reviews. 2010;15(4):331–41. DOI: 10.1007/s10741-009-9140-3.

Ueland T., Gullestad L., Nymo S.H., et al. Inflammatory cytokines as biomarkers in heart failure. Clin. Chim. Acta. 2015;443:71–7. DOI: 10.1016/j.cca.2014.09.001.

Vaz Pérez A., Doehner W., Haehling S., et al. The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int. J. Cardiol. 2010;141(1):39–43. DOI: 10.1016/j.ijcard.2008.11.146.

Ren M., Li X., Hao L., Zhong J.. Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target? Ann. Med. Informa Healthcare. 2015;47(4):316–24. DOI: 10.3109/07853890.2015.1042030.

Scott L., Li N., Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int. J. Cardiol. 2019;287:195–200. DOI: 10.1016/j.ijcard.2018.10.020.

Bradham W.S., Bozkurt B., Gunasinghe H., et al. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: A current perspective. Cardiovasc. Res. 2002. 53 (4): 822-830. DOI: 10.1016/s0008-6363(01)00503-x.

Deng H., Xue Y.M., Zhan X.Z., et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. Chin Med J (Engl). 2011;124(13):1976-82. DOI: 10.3760/cma.j.issn.0366-6999.2011.13.010.

Bautista L.E., Vera L.M., Arenas I.A., et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J. Hum. Hypertens. 2005;19(2):149–54. DOI: 10.1038/sj.jhh.1001785.

Satou R., Miyata K., Katsurada A., et al. Tumor necrosis factor-α suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells. Am. J. Physiol. — Cell Physiol. 2010;299(4):750-9. DOI: 10.1152/ajpcell.00078.2010.

Zhang W., Li X.-J., Zeng X., et al. Activation of nuclear factor-κB pathway is responsible for tumor necrosis factor-α-induced up-regulation of endothelin B2 receptor expression in vascular smooth muscle cells in vitro. Toxicol. Lett. 2012;209(2):107-12. DOI: 10.1016/j.toxlet.2011.12.005.

Jayaraj R.L., Azimullah S., Beiram R., et al. Neuroinflammation: Friend and foe for ischemic stroke. J. Neuroinflammation. 2019;16(1):142. DOI: 10.1186/s12974-019-1516-2.

Swaroop J.J., Rajarajeswari D., Naidu J.N. Association of TNF-α with insulin resistance in type 2 diabetes mellitus. Indian J. Med. Res. 2012;135(1):127-30. DOI: 10.4103/0971-5916.93435.

Akash M.S.H., Rehman K., Liaqat A. Tumor Necrosis FactorAlpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J. Cell. Biochem. 2018;119(1):105–10. DOI: 10.1002/jcb.26174.

Zhang L., Wheatley C.M., Richards S.M., et al. TNF-α acutely inhibits vascular effects of physiological but not high insulin or contraction. Am. J. Physiol. — Endocrinol. Metab. 2003;285(3):E654-660. DOI: 10.1152/ajpendo.00119.2003.

Li G., Barrett E.J., Barrett M.O., et al. Tumor necrosis factor-α induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007;148(7):3356-63. DOI: 10.1210/en.2006-1441.

Amdur R.L., Feldman H.I., Gupta J., et al. Inflammation and progression of CKD: The CRIC study. Clin J Am Soc Nephrol. 2016;11(9):1546-56. DOI: 10.2215/CJN.13121215.

Yu X., Yang Z., Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Ren. Fail. 2010;32:475–9. DOI: 10.3109/08860221003664280.

Carlsson A.C., Larsson T.E., Helmersson-Karlqist J., et al. Soluble TNF Receptors and Kidney Dysfunction in the Elderly. J Am Soc Nephrol. 2014;25(6);1313–20. DOI: 10.1681/ASN.2013080860.

Zhao B. TNF and Bone Remodeling. Curr. Osteoporos. Rep. 2017;15(3):126–34. DOI: 10.1007/s11914-017-0358-z.

Reid M.B., Li Y.P. Tumor necrosis factor-α and muscle wasting: A cellular perspective. Respir. Res. 2001;2(5):269–72. DOI: 10.1186/rr67.

Michaud M., Balardy L., Moulis G., et al. Proinflammatory cytokines, aging, and age-related diseases. J. Am. Med. Dir. Assoc. 2013;14(12):877–82. DOI: 10.1016/j.jamda.2013.05.009.

Marzetti E., Calvani R., Cesari M., et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int. J. Biochem. Cell Biol. 2013;45(10):2288- 301. DOI: 10.1016/j.biocel.2013.06.024.

MacCiò A., Madeddu C. Management of Anemia of inflammation in the elderly. Anemia. 2012; 2012:563251. DOI: 10.1155/2012/563251.

Davizon-Castillo P., McMahon D., Aguila S., et al. TNF-αdriven inflammation and mitochondrial dysfunction define the platelet hypereactivity of aging. Blood. 2019:134(9):727-40. DOI: 10.1182/blood.2019000200.

Lindbergh C.A., Casaletto K.B., Staffaroni A.M., et al. Systemic tumor necrosis factor-alfa trajectories relate to brain health in typically aging older adults. The Journals of Gerontology: Series A. 2019;glz209. DOI: 10.1093/gerona/glz209.

The authors declare that there are no conflicts of interest present.